RxDoctor Payments Data

Cassandra Suggs, MD

Family Medicine · Reynoldsburg, OHNPI 1942255781

Payments from drug & device makers

$9,767in general payments, 2019–2025

Across 656 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$846
  • GSK$737
  • Pfizer$498
  • Sanofi-aventis U.S. LLC$482
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$9,66199%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,767 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$112,623
Medicare patients
150
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$155,731
FarxigaDapagliflozin Propanediol97$91,555
TrulicityDulaglutide47$69,260
EliquisApixaban69$52,036
Tresiba Flextouch U-200Insulin Degludec38$50,275
JardianceEmpagliflozin65$49,963
MounjaroTirzepatide33$34,471
JanuviaSitagliptin Phosphate27$27,265
LinzessLinaclotide18$23,030
MyrbetriqMirabegron17$20,318
Tresiba Flextouch U-100Insulin Degludec19$19,276
TradjentaLinagliptin13$16,785
XareltoRivaroxaban11$14,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,647
Breo ElliptaFluticasone/Vilanterol15$7,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,712$155,731115 claims
Lilly USA, LLCTrulicity, Mounjaro$374$103,73180 claims
AstraZenecaFarxiga, Symbicort$846$96,720108 claims
Boehringer IngelheimJardiance, Tradjenta$448$66,74978 claims
PfizerEliquis$498$52,03669 claims
MerckJanuvia, Dulera$151$32,82239 claims
AbbVieLinzess, Synthroid$1,415$26,05658 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$737$21,10945 claims
Astellas Pharma US IncMyrbetriq$297$20,31817 claims
Johnson & JohnsonXarelto$130$14,64211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Reynoldsburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →